AdaptHealth Corp. Investigation
Company: AdaptHealth Corp.
Ticker: (NASDAQ) AHCO
How to Check Whether You May Be Eligible in the AdaptHealth Corp. Investigation
Investigation Details
AdaptHealth Corp. shares fell as much as 26% after the Company reported second quarter revenue of $740.3 million, well below approximately $847 million expected, a GAAP loss driven in part by a $144.2 million goodwill impairment charge, and a substantial reduction to full-year guidance.
Adjusted EBITDA came in at $132 million for the quarter, against roughly $160 million expected. Alongside those results, AdaptHealth reset its 2026 continuing-operations outlook to approximately $2.85 billion to $2.89 billion in revenue and $490 million to $520 million in adjusted EBITDA. Management attributed the reset to the Diabetes Health divestiture, a capitated contract, manufacturer pricing, and other portfolio actions.
The investigation concerns the scale of that exposure. The reduced revenue range represents a decline of roughly 16% to 19% from the guidance figures the Company had carried weeks earlier.